CLINICAL TRIAL: MODULATION OF TECHNETIUM-99M MEBROFENIN HEPATIC TRANSPORT TO RIT

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这将是一项开放标签、随机、交叉临床研究，受试者为任何种族的男性和女性健康志愿者，调查单剂量利托那韦（一种已知的肝脏转运活性调节剂）对 Technetium Tc-99m 甲布罗宁处置的影响。 使用伽马发射器 Technetium Tc-99 mebrofenin 将可以实时评估胆汁排泄、胆囊射血分数和胆汁收集的效率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be an open-label, randomized, crossover clinical study in male and female healthy volunteers of any ethnicity investigating the effect of a single dose of ritonavir, a known modulator of hepatic transport activity, on the disposition of Technetium Tc-99m mebrofenin. The use of the gamma emitter Technetium Tc-99 mebrofenin will allow real-time assessment of biliary excretion, gallbladder ejection fraction, and the efficiency of bile collection.